Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria

Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fracti...

Descripción completa

Detalles Bibliográficos
Autores: Camps-Vilaró, Anna, Delgado-Jiménez, Juan F., Farré López, Núria, Tizón-Marcos, Helena, Álvarez-García, Jesus, Cinca, Juan, Dégano, Irene R., Marrugat, Jaume, 1954-
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/45361
Acceso en línea:http://hdl.handle.net/10230/45361
http://dx.doi.org/10.3390/jcm9072089
Access Level:acceso abierto
Palabra clave:Cardiovascular disease
Cardiovascular therapy
Dapagliflozin
Epidemiology
Heart failure
Prevalence
Reduced ejection fraction
Sodium-glucose cotransporter-2 inhibitor
id ES_06bdf3f79fa2ba67acee939faef27166
oai_identifier_str oai:repositori.upf.edu:10230/45361
network_acronym_str ES
network_name_str España
repository_id_str
spelling Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study CriteriaCamps-Vilaró, AnnaDelgado-Jiménez, Juan F.Farré López, NúriaTizón-Marcos, HelenaÁlvarez-García, JesusCinca, JuanDégano, Irene R.Marrugat, Jaume, 1954-Cardiovascular diseaseCardiovascular therapyDapagliflozinEpidemiologyHeart failurePrevalenceReduced ejection fractionSodium-glucose cotransporter-2 inhibitorHeart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fraction (EF) in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Our aim was to estimate the number of patients with DAPA-HF characteristics in Spain. Our literature review identified epidemiological studies whose objective was to quantify the prevalence of HF and its comorbidities in Spain. We estimated the prevalence of HF with reduced EF, of New York Heart Association (NYHA) functional class II-IV, and with a glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m². In this population, we analysed the prevalence of diabetes using data from the REDINSCOR (Spanish Network for Heart Failure) registry. Our estimations indicate there are 594,684 patients ≥45 years old with HF in Spain (2.6% of this population age group), of which 52.4%, 84.0%, and 93.9% have reduced EF, are NYHA II-IV, and have a GFR ≥ 30 mL/min/1.73 m², respectively. By our calculations, approximately 245,789 Spanish patients would meet the DAPA-HF patient profile, and therefore could benefit from the protective cardiovascular effects of dapagliflozin.MDPI202020202020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/45361http://dx.doi.org/10.3390/jcm9072089reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésCopyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/453612026-06-12T07:21:37Z
dc.title.none.fl_str_mv Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
title Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
spellingShingle Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
Camps-Vilaró, Anna
Cardiovascular disease
Cardiovascular therapy
Dapagliflozin
Epidemiology
Heart failure
Prevalence
Reduced ejection fraction
Sodium-glucose cotransporter-2 inhibitor
title_short Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
title_full Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
title_fullStr Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
title_full_unstemmed Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
title_sort Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
dc.creator.none.fl_str_mv Camps-Vilaró, Anna
Delgado-Jiménez, Juan F.
Farré López, Núria
Tizón-Marcos, Helena
Álvarez-García, Jesus
Cinca, Juan
Dégano, Irene R.
Marrugat, Jaume, 1954-
author Camps-Vilaró, Anna
author_facet Camps-Vilaró, Anna
Delgado-Jiménez, Juan F.
Farré López, Núria
Tizón-Marcos, Helena
Álvarez-García, Jesus
Cinca, Juan
Dégano, Irene R.
Marrugat, Jaume, 1954-
author_role author
author2 Delgado-Jiménez, Juan F.
Farré López, Núria
Tizón-Marcos, Helena
Álvarez-García, Jesus
Cinca, Juan
Dégano, Irene R.
Marrugat, Jaume, 1954-
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cardiovascular disease
Cardiovascular therapy
Dapagliflozin
Epidemiology
Heart failure
Prevalence
Reduced ejection fraction
Sodium-glucose cotransporter-2 inhibitor
topic Cardiovascular disease
Cardiovascular therapy
Dapagliflozin
Epidemiology
Heart failure
Prevalence
Reduced ejection fraction
Sodium-glucose cotransporter-2 inhibitor
description Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fraction (EF) in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Our aim was to estimate the number of patients with DAPA-HF characteristics in Spain. Our literature review identified epidemiological studies whose objective was to quantify the prevalence of HF and its comorbidities in Spain. We estimated the prevalence of HF with reduced EF, of New York Heart Association (NYHA) functional class II-IV, and with a glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m². In this population, we analysed the prevalence of diabetes using data from the REDINSCOR (Spanish Network for Heart Failure) registry. Our estimations indicate there are 594,684 patients ≥45 years old with HF in Spain (2.6% of this population age group), of which 52.4%, 84.0%, and 93.9% have reduced EF, are NYHA II-IV, and have a GFR ≥ 30 mL/min/1.73 m², respectively. By our calculations, approximately 245,789 Spanish patients would meet the DAPA-HF patient profile, and therefore could benefit from the protective cardiovascular effects of dapagliflozin.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/45361
http://dx.doi.org/10.3390/jcm9072089
url http://hdl.handle.net/10230/45361
http://dx.doi.org/10.3390/jcm9072089
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402936347459584
score 15,811543

Similares en LA Referencia